|
Jan 22
|
3 Promising US Penny Stocks With Market Caps Under $900M
|
|
Jan 21
|
AbCellera to Report Full Year 2024 Financial Results on February 27, 2025
|
|
Jan 20
|
AbCellera Biologics Inc. (NASDAQ:ABCL) most popular amongst individual investors who own 36% of the shares, institutions hold 29%
|
|
Jan 17
|
AbCellera Biologics Inc. (ABCL): A Bull Case Theory
|
|
Jan 15
|
AbbVie and Simcere Zaiming link to develop trispecific antibody
|
|
Sep 26
|
AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024
|
|
Aug 29
|
AbCellera to Present at Upcoming Investor Conferences in September
|
|
Aug 29
|
AbCellera Biologics Inc. (ABCL): A Top Contender Among Canada’s Best Penny Stocks in 2024
|
|
Jun 25
|
AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024
|
|
Jun 13
|
Down 57%, Is AbCellera Biologics a Buy on the Dip?
|
|
Jun 6
|
We're Not Very Worried About AbCellera Biologics' (NASDAQ:ABCL) Cash Burn Rate
|
|
May 28
|
AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024
|
|
May 10
|
Earnings Release: Here's Why Analysts Cut Their AbCellera Biologics Inc. (NASDAQ:ABCL) Price Target To US$12.71
|
|
May 8
|
AbCellera Biologics Inc. (NASDAQ:ABCL) Q1 2024 Earnings Call Transcript
|
|
May 8
|
Q1 2024 Abcellera Biologics Inc Earnings Call
|
|
May 8
|
AbCellera Biologics (ABCL) Q1 2024 Earnings Call Transcript
|
|
May 7
|
AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Misses Revenue Estimates
|
|
May 7
|
AbCellera Biologics Inc (ABCL) Q1 2024 Earnings: Misses Revenue and Net Loss Estimates
|
|
May 7
|
AbCellera Reports Q1 2024 Business Results
|
|
May 2
|
Insider Stock Buying Reaches US$1.61m On AbCellera Biologics
|